Huoxiang anwei Capsule for the treatment of Helicobacter pylori infection in a randomized controlled clinical study
- Conditions
- Helicobacter pylori infection
- Registration Number
- ITMCTR2200006151
- Lead Sponsor
- Spleen and Stomach Department, Shenzhen Hospital of Traditional Chinese Medicine, No. 1 fuhua Road, Futian District, Shenzhen city
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Meet the diagnostic criteria for Hp infection;
(2) 18-65 years old;
(3) Voluntarily accept the experiment and sign the informed consent.
(1) Patients with serious lesions of heart, liver and kidney, hematopoietic system diseases and tumors;
(2) Antibiotics, acid suppressants and bismuth were used within 4 weeks before treatment;
(3) Systemic diseases that affect the motility of the digestive tract (e.g., hyperthyroidism, diabetes, chronic renal insufficiency, mental and neurological disorders)
Pathological changes, etc.);
(4) those with a history of abdominal surgery (except appendectomy and cesarean section);
(5) pregnant or planning to be pregnant, breast-feeding women;
(6) Those who have a history of drug allergy or severe food allergy used in the study;
Project Name: Huoxiang Anwei Capsule in the treatment of Helicobacter pylori infection randomized controlled clinical study Version no. : Version 1.0 Date: 20220330
3/5
(7) have a history of neurological and mental diseases;
(8) Subjects who are participating in other clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Helicobacter pylori results;
- Secondary Outcome Measures
Name Time Method